Effect of pirfenidone against vanadate-induced kidney fibrosis in rats

被引:43
作者
Al-Bayati, MA
Xie, Y
Mohr, FC
Margolin, SB
Giri, SN [1 ]
机构
[1] Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA
[2] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA
[3] Marnac Inc, Dallas, TX 75231 USA
关键词
kidney fibrosis; pirfenidone; vanadate; rats;
D O I
10.1016/S0006-2952(02)01213-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Renal fibrosis is a complication of kidney injury and can contribute to organ failure. Currently, there are no drugs for the treatment of renal fibrosis. Pirfenidone (PD) has been proven to have antifibrotic effects in animal models of fibrosis. We tested the ability of PD against; vanadate-induced kidney fibrosis in rats. The rats were injected subcutaneously with vehicle or vanadate solution (1 mg vanadate/kg/day) for 12 or 16 days to produce varying degrees of kidney fibrosis. The vanadate- and vehicle-treated rats were fed a laboratory diet or the same diet mixed with 0.6% PD ad lib. One vanadate-injected group was initially fed the same diet without PD and later switched to the diet containing PD 2 days after the last injection. The rats were killed at 12 and 25 days following the last dose. The changes found in the kidney of vanadate-treated rats included increases in RNA and DNA content and increases in kidney weight. Treatment with PD diminished the vanadate-induced increases in kidney weight and RNA content. The hydroxyproline content of the kidney in vanadate-treated animals was increased significantly (P less than or equal to 0.05) from the control level of 1452 mug/kidney to 1765 mug/kidney. Treatment with PD for 37 days caused significant reductions in the vanadate-induced increases in the hydroxyproline level. Similarly, treatment for 41 days also caused significant reductions (1744 mug/kidney) in vanadate-induced increases in the hydroxyproline level (1996 mug/kidney). The histological evaluation revealed that the severity of the lesions in the vanadate-treated group was moderate to severe, and treatment with PD for 41 days decreased the severity to a mild level. In addition, the delayed treatment with PD also minimized the vanadate-induced increases in the collagen content of the kidney. Although it is speculative, PD may potentially be therapeutic in the management of renal fibrosis. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:517 / 525
页数:9
相关论文
共 54 条
  • [1] AL-BAYATI M A, 1989, Journal of Environmental Pathology Toxicology and Oncology, V9, P435
  • [2] BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
  • [3] Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells
    Barchowsky, A
    Dudek, EJ
    Treadwell, MD
    Wetterharn, KE
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 1996, 21 (06) : 783 - 790
  • [4] Beyhl F E, 1983, Arch Toxicol Suppl, V6, P250
  • [5] EVIDENCE FOR FREE-RADICAL INVOLVEMENT IN HYDROXYLATION OF PROLINE - INHIBITION BY NITRO BLUE TETRAZOLIUM
    BHATNAGA.RS
    LIU, TZ
    LUSSAN, C
    [J]. FEBS LETTERS, 1972, 26 (01) : 32 - &
  • [6] BLEOMYCIN REGULATION OF TRANSFORMING GROWTH-FACTOR-BETA MESSENGER-RNA IN RAT LUNG FIBROBLASTS
    BREEN, E
    SHULL, S
    BURNE, S
    ABSHER, M
    KELLEY, J
    PHAN, S
    CUTRONEO, KR
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1992, 6 (02) : 146 - 152
  • [7] TRANSFORMING GROWTH FACTOR-BETA-1 IS PRESENT AT SITES OF EXTRACELLULAR-MATRIX GENE-EXPRESSION IN HUMAN PULMONARY FIBROSIS
    BROEKELMANN, TJ
    LIMPER, AH
    COLBY, TV
    MCDONALD, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (15) : 6642 - 6646
  • [8] Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone
    Cain, WC
    Stuart, RW
    Lefkowitz, DL
    Starnes, JD
    Margolin, S
    Lefkowitz, SS
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1998, 20 (12): : 685 - 695
  • [9] Long-term outcome in children and adults with classic focal segmental glomerulosclerosis
    Cattran, DC
    Rao, P
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (01) : 72 - 79
  • [10] CHAN P C K, 1991, International Urology and Nephrology, V23, P619